Provectus Biopharmaceuticals (PVCT)
(Delayed Data from OTC)
$0.17 USD
-0.01 (-8.01%)
Updated Jun 7, 2024 03:37 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PVCT 0.17 -0.01(-8.01%)
Will PVCT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PVCT based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for PVCT
Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting
Provectus announces presentation at RBS for full-thickness cutaneous wounds
Provectus: Q1 Earnings Snapshot
PVCT Stock Earnings: Provectus Reported Results for Q1 2024
Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting